drugset
drugset / Trial / NCT04713176

Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients

NCT04713176 ↗

Phase 3 Terminated 240 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupDouble-blindTreatment

Summary

Efficacy and Safety of DWJ1248 with Remdesivir in Severe COVID-19 Patients

Timeline

Start
2021-02-02
Primary completion
2022-05-02
Completion
2022-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject DWJ1248 Unknown 1 unknown Oral
Background Remdesivir Small molecule — Intravenous

Indications

COVID-19